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ABSTRACT
Introduction: Impact of demographics and
socioeconomic status (SES) on anticoagulant
treatment outcomes among patients with
venous thromboembolism (VTE) is not well
understood. This study evaluated risks of
recurrent VTE, major bleeding (MB), and clini-
cally relevant non-major bleeding (CRNMB)
among older patients with VTE initiating
apixaban or warfarin stratified by demographics
and SES.
Methods: Adult patients (C 65 years) who ini-
tiated apixaban or warfarin after a VTE event
were selected from the US CMS Medicare data-
base (September 2014–December 2017). Stabi-
lized inverse probability treatment weighting
(IPTW) was used to balance patient character-
istics between treatment cohorts. Patients were
stratified by age, gender, race, and SES. For each
subgroup, Cox proportional hazard models
were used to evaluate if there was a significant
interaction (p\ 0.10) between treatment and
subgroup for recurrent VTE, MB, and CRNMB.
Results: In total, 22,135 apixaban and 45,840
warfarin patients with VTE were included. Post-
IPTW, patient characteristics were balanced
between treatment cohorts. In older patients,
apixaban treatment was associated with signifi-
cantly lower risks of recurrent VTE (hazard ratio
[HR] 0.64; 95% confidence interval [CI]
0.52–0.79), MB (HR 0.65; 95% CI 0.57–0.75),
and CRNMB (HR 0.79; 95% CI 0.75–0.85) versus
warfarin. When stratified by demographics and
SES, higher incidence rates of recurrent VTE,
MB, and CRNMB were observed for black vs
white patients and patients with lower vs higher
SES. Comparison of apixaban with warfarin by
different demographic and SES subgroups
showed generally consistent results as the
overall analysis. For most subgroups, no signif-
icant interaction was observed between
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treatment and subgroup strata for recurrent
VTE, MB, and CRNMB.
Conclusion: Among older patients with VTE
initiating apixaban or warfarin, higher rates of
recurrent VTE and bleeding were observed in
black patients and patients with lower SES.
Apixaban had a lower risk of recurrent VTE, MB,
and CRNMB compared to warfarin. Analyses of
demographic and SES subgroups showed con-
sistent findings.




Why carry out this study?
Venous thromboembolism (VTE) is a
common cause of preventable deaths in
older hospitalized patients.
There has been a lack of evidence about
potential impact of demographics and
socioeconomic status on anticoagulant
treatment outcomes in patients with VTE.
This study aimed to evaluate the risk of
recurrent VTE, major bleeding (MB), and
clinically relevant non-MB (CRNMB)
among older patients with VTE initiating
apixaban or warfarin stratified by
demographics and socioeconomic status
in routine clinical practice.
What was learned from this study?
Among older patients with VTE, black
patients and those with lower
socioeconomic status tended to have
higher incidence rates of recurrent VTE,
MB, and CRNMB compared to their
counterparts.
When compared to warfarin, apixaban
had a lower risk of recurrent VTE, MB, and
CRNMB among patients with VTE.




Venous thromboembolism (VTE) is a common
cause of preventable death especially in older
hospitalized patients [1, 2]. Acquired risk factors
for VTE include age, obesity, smoking, surgery,
immobility, hospitalization, pregnancy, hor-
mone therapy, malignancy, and other comor-
bid medical conditions [3]. There exist racial
differences in the incidence of VTE—black
patients have a significantly higher rate of VTE
and a higher rate of complications such as
death, major bleeding (MB), and recurrent VTE
compared to white patients [4–6]. Another
study showed that black Americans had a
30–60% higher incidence rate of VTE than
white Americans despite having lower rates of
the two genetic mutations known to increase
the risk of VTE [7]. While VTE can occur in all
races, gender, and age groups, there is a signif-
icantly higher prevalence of VTE among black
and older patients [8, 9].
Clinical guidelines recommend the use of
direct oral anticoagulants (DOACs; including
apixaban, dabigatran, edoxaban, rivaroxaban)
and warfarin for the treatment of VTE [10, 11].
However, the effects of demographics and
socioeconomic status (SES) on DOAC treatment
outcomes are not well understood. Some studies
have found associations between SES and the
use of DOACs vs vitamin K antagonist in
patients with VTE—patients with a lower
household income were less likely to use
DOACs compared to those with a higher
household income [12]. The difference in
DOAC treatment rate by SES may lead to dis-
parity in health outcomes such as the risk of
developing recurrent VTE. Additionally,
patients may respond to anticoagulant treat-
ments differently because of different age, gen-
der, race, and SES.
However, few clinical trials and real-world
studies have evaluated the impact of demo-
graphics and SES on anticoagulant treatment
outcomes among patients with VTE. Minorities
and patients with lower SES have been under-
represented in clinical trials [13], and evidence
on the effectiveness and safety of anticoagu-
lants in patients with VTE with different
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demographics and SES is sparse. Therefore, this
study aimed to evaluate the risk of recurrent
VTE, MB, and clinically relevant non-major
bleeding (CRNMB) among older patients with
VTE initiating apixaban or warfarin stratified by
demographics and SES in routine clinical
practice.
METHODS
Data Source and Patient Selection
This retrospective analysis utilized data from
the United States (US) Centers for Medicare and
Medicaid Services (CMS) fee-for-service Medi-
care database. Patients with a VTE diagnosis
(based on International Classification of Dis-
eases, 9th and 10th Revision codes) in any
position in the inpatient or outpatient setting
were identified between September 1, 2014 and
December 31, 2017. Patients were required to
have at least one pharmacy claim for apixaban
or warfarin during the 30-day period following
the index VTE event. The first warfarin or
apixaban prescription claim was designated as
the index date. Patients aged at least 65 years on
the index date with continuous health plan
enrollment, including medical and pharmacy
benefits, for at least 6 months before the index
VTE event until the index date were included in
the study population. Additional selection cri-
teria are listed in Fig. 1.
The baseline period was defined as 6 months
prior to and including the index date; the fol-
low-up period included the day after the index
date through the earliest of index therapy dis-
continuation, switch to another oral anticoag-
ulant or parenteral anticoagulant, health plan
disenrollment, death, the end of the study per-
iod, or 6-months post-index date. This study
employed an on-treatment approach and
therefore did not consider events that occurred
after a patient switched or discontinued index
treatment.
Study Variables
Recurrent VTE and MB were defined by primary
diagnosis in the inpatient setting [14–18].
CRNMB was identified by either an inpatient
admission with a secondary diagnosis code for
non-critical sites of bleeding (excluded if MB
occurred before the CRNM bleed or during the
same hospitalization) or by a diagnosis code for
gastrointestinal bleeding or other selected non-
critical site of bleeding in the outpatient setting.
This approach aligns with the current recom-
mendation of the International Society on
Thrombosis and Haemostasis [14–19].
Demographic variables including age, gen-
der, and race were measured on the index date.
Age was categorized as 65–79 years
and C 80 years. Gender was categorized as male
and female. Race was categorized as white,
black, and other race (including Asian, Hispan-
ics, North American native, other, and
unknown races). Two SES factors were consid-
ered—one was Medicare Medicaid dual eligibil-
ity or Part D low income subsidy (LIS) anytime
during the baseline period. Another was SES
status constructed for each US zip code using
data on income, education, and occupation
from the 2015 US census. This information was
then linked to the patient’s zip code of resi-
dence on the index date to define the SES for
the patient [20, 21]. Clinical characteristics
(such as the Deyo–Charlson comorbidity index,
baseline comorbidities, falls, fracture/trauma
involving lower extremities, selected surgeries,
and baseline medications) were evaluated dur-
ing the baseline period. VTE-related variables
such as type of index VTE event and index VTE
diagnosis were measured during the index VTE
event date.
Statistical Methods
Patient characteristics were balanced between
the treatment cohorts using stabilized inverse
probability treatment weighting (IPTW); base-
line demographics, clinical characteristics, and
VTE-related variables were covariates included
in the model. IPTW weights were stabilized by
multiplying the original weights with a
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constant that was equal to the expected value of
being in the treatment or comparison cohorts
[22–24]. The risk of recurrent VTE, MB, and
CRNMB was evaluated by using Cox propor-
tional hazard models. Interaction analyses were
conducted using Cox models to evaluate whe-
ther treatment effects differ by age (65–79 vs
C 80 years), gender (male vs female), race (white
vs black), SES (low vs medium vs high), and dual
Medicare/Medicaid eligibility or Part-D LIS (yes
vs no). For each of the demographic and SES
subgroups, a statistical significance (p\0.10) of
the interaction between the treatment and
subgroup strata on effectiveness and safety was
evaluated.
Compliance with Ethics Guidelines
This retrospective database analysis did not
involve the collection, use, or transmittal of
individual identifiable data. As such, institu-
tional review board (IRB) approval to conduct
this study was not required and considered
exempt according to 45CFR46.101(b)(4): exist-
ing data and specimens—no identifiers. Both
the data set itself and the security of the offices
where the data are housed meet the require-
ments of the Health Insurance Portability and
Accountability Act (HIPAA) of 1996.
Fig. 1 Patient selection criteria
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RESULTS
During the study period, approximately
1.4 million patients had a VTE event in the
Medicare database; after application of the
selection criteria, 22,135 (32.6%) patients who
initiated apixaban and 45,840 (67.4%) patients
who initiated warfarin were included in the
study (Fig. 1). Table 1 shows demographics, SES,
and clinical characteristics for the apixaban and
warfarin cohorts before and after IPTW. After
IPTW, all patient characteristics were well bal-
anced (Table 1). For both treatment cohorts,
most patients were aged 65–79 years (apixaban,
62.6%; warfarin, 62.6%), followed by C 80 years
(apixaban, 37.4%; warfarin, 37.4%). The
majority of patients were female (apixaban,
62.9%; warfarin, 62.9%) and white (apixaban,
84.2%; warfarin, 83.7%) across the two cohorts.
The largest proportion of patients had a high
SES (apixaban, 45.2%; warfarin, 42.2%), fol-
lowed by medium (apixaban, 30.2%; warfarin,
32.6%), and low (apixaban, 22.7%; warfarin,
23.4%). One-third of patients also had Medi-
care/Medicaid dual-eligibility and/or Part D low
income subsidy (apixaban, 28.5%; warfarin,
30.5%) during the baseline period. During the
follow-up period, apixaban patients had signif-
icantly lower risk of recurrent VTE (hazard ratio
[HR] 0.64; 95% confidence interval [CI]
0.52–0.79), MB (HR 0.65; 95% CI 0.57–0.75),
and CRNMB (HR 0.79; 95% CI 0.75–0.85)
compared to warfarin patients.
The baseline characteristics for older patients
with VTE on apixaban vs warfarin stratified by
age, gender, race, SES status, and dual eligibil-
ity/Part-D LIS are listed in Supplemental Mate-
rial. For both apixaban and warfarin cohorts,
higher mean comorbidity index was observed in
patients aged C 80 vs 65–79 years (apixaban,
3.2 vs 2.7; warfarin, 3.2 vs 2.7), low vs high SES
(apixaban, 3.5 vs 2.6; warfarin, 3.3 vs 2.7), and
dual eligibility/Part-D LIS yes vs no (apixaban,
3.9 vs 2.5; warfarin, 3.8 vs 2.5) and black vs
white patients (apixaban, 4.1 vs 2.7; warfarin,
4.1 vs 2.7). Additionally, during the follow-up,
the incidence rates per 100 person-years for
recurrent VTE were numerically higher for black
vs white patients (apixaban, 2.0 vs 1.4; warfarin,
3.3 vs 2.2) and patients with low vs high SES
(apixaban, 2.6 vs 1.3; warfarin, 3.2 vs 2.0) and
dual eligibility/Part-D LIS yes vs no (apixaban,
2.2 vs 1.3; warfarin, 3.1 vs 2.0) (Fig. 2). Similarly,
the incidence rates per 100 person-years for MB
were numerically higher for patients aged C 80
vs 65–79 years (apixaban, 5.4 vs 3.1; warfarin,
7.4 vs 5.0), female vs male (apixaban, 4.5 vs 3.1;
warfarin, 6.4 vs 5.0), black vs white patients
(apixaban, 7.4 vs 3.5; warfarin 10.1 vs 5.3), low
vs high SES (apixaban, 5.7 vs 3.2; warfarin, 7.0
vs 5.1), and dual eligibility/Part-D LIS yes vs no
(apixaban, 6.3 vs 3.1; warfarin, 8.6 vs 4.8)
(Fig. 3).
Figures 2, 3, and 4 show the data of apixaban
vs warfarin on risks of recurrent VTE, MB, and
CRNMB stratified by demographic and SES fac-
tors. No significant interaction was observed
between the treatment and the following sub-
groups on recurrent VTE (Fig. 2) and MB (Fig. 3):
age, sex, race, SES, and dual eligibility/LIS.
Across all subgroup strata, apixaban patients
had a lower incidence rate of recurrent VTE and
MB compared to warfarin patients. For CRNMB,
no significant interaction was observed between
the treatment and the following subgroups: sex,
race, and dual eligibility/LIS (Fig. 4). However,
there were significant interactions between the
treatment and age (interaction p value = 0.001)
and between the treatment and SES (interaction
p value = 0.012) on CRNMB. Apixaban trended
towards a lower risk of CRNMB across both age
groups, but the treatment effect on CRNMB was
larger for patients aged 65–79 years. Similarly,
apixaban trended towards a lower risk of
CRNMB across all three SES strata, but the
treatment effect was larger for those with med-
ium and high SES (Fig. 4).
DISCUSSION
There has been a lack of evidence about the
potential impact of demographic and SES fac-
tors on anticoagulant treatment outcomes in
patients with VTE. To help fill in some of the
evidence gaps, this study compared the risk of
recurrent VTE, MB, and CRNMB among older
patients with VTE who initiated apixaban vs
warfarin stratified by demographic and SES
Adv Ther (2021) 38:5519–5533 5523
Table 1 Baseline and clinical characteristics among older patients with VTE that initiated apixaban vs warfarin pre and
post IPTW










Sample size 45,840 22,135 45,840 22,135
Age (in years), mean (SD) 77.2 (8.1) 77.7 (8.2) 6.01 77.3 (8.1) 77.4 (8.2) 1.57







































































































Medicare/Medicaid dual-eligibility and/or Part D low










Type of index VTE event, n (%)
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Table 1 continued
























































Deyo–Charlson comorbidity index, mean (SD) 2.9 (2.5) 2.9 (2.5) 1.40 2.9 (2.5) 2.9 (2.5) 0.37
Baseline comorbidity, n (%)
AIDS 128
(0.3%)
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Table 1 continued























































Spinal cord injury 130
(0.3%)
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Table 1 continued





































































































































AIDS acquired immunodeficiency syndrome, COPD chronic obstructive pulmonary disorder, DVT deep vein thrombosis,
ESRD end stage renal disease, IPTW inverse probability of treatment weighting, NSAIDs nonsteroidal anti-inflammatory
drugs, PE pulmonary embolism, SERMS selective estrogen receptor modulators, SES socioeconomic status, SD standard
deviation, STD standardized differences, VTE venous thromboembolism
*STD = 100 9 |actual standardized difference|. Standardized difference (STD) greater than 10 was considered significant
**After weightings were applied, the values for the baseline variables were not whole numbers; therefore, as a result of
rounding the sum of patients may not equal 100%
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factors including age, sex, race, SES, and dual
eligibility/Part-D LIS. In patients with VTE
aged C 65 years, apixaban was associated with
significantly lower risk of recurrent VTE, MB,
and CRNMB compared to warfarin. When
stratified by the demographic and socioeco-
nomic factors, black patients and patients with
lower SES tended to have higher incidence rates
of recurrent VTE, MB, and CRNMB than their
respective counterparts for both apixaban and
warfarin cohorts. Comparisons of apixaban
with warfarin on recurrent VTE and MB by the
demographic and socioeconomic factors show
no significant interaction between the treat-
ment and the following subgroups: age, sex,
race, SES, and dual eligibility/Part-D LIS. Two
significant interactions were observed for
CRNMB, but apixaban patients trended towards
a lower risk of CRNMB across all subgroup
strata.
Our findings are generally consistent with
the age and gender subgroup analysis of the
AMPLIFY clinical trial. AMPLIFY demonstrated
that apixaban was noninferior to enoxaparin
followed by warfarin for the treatment of VTE
and was associated with significantly less
bleeding among patients with VTE [13]. For
AMPLIFY, approximately 58% of patients were
male with an average age of 57 years [13]. In the
subgroup analysis of AMPLIFY, there was no
significant interaction between treatment and
age subgroups (aged\ 65 years, 65–74 years,
and C 75 years, interaction p = 0.3427) as well
as between treatment and gender (interaction
p = 0.4514) with regards to recurrent VTE or
VTE-related death [13]. There was also no sig-
nificant interaction between treatment and age
(interaction p = 0.8174) or between treatment
and gender (interaction p = 0.4168) with
regards to MB [13]. Consistently, our study did
not observe significant interactions between the
Fig. 2 Risk of recurrent VTE among older patients with VTE stratified by demographic and socioeconomic factors.
CI: confidence interval
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treatment and age or gender for recurrent VTE
or MB.
Race has been found to be a risk factor for
VTE and racial disparity in VTE event rates has
been well documented in the literature [25–27].
In general, black patients were found to have a
higher incidence and risk of VTE compared to
white patients [25–27] possibly due to underly-
ing risk factors for VTE compared to white
patients as well as low adherence to treatment
[28]. Consistent with this, the current study
found that black patients had a higher inci-
dence rate per 100 person-years for recurrent
VTE compared to white patients. Additionally,
we found a higher incidence rate of MB and
CRNMB for black vs white patients. A previously
published single-center study also showed that
among DVT patients, race (non-white race—
relative hazard 1.6; 95% CI 1.2–2.1) was a risk
factor for bleeding during hospitalization [29].
Despite the higher risk of VTE among black
patients, a retrospective study found that black
patients with VTE were significantly less likely
to receive a DOAC treatment compared to white
patients (odds ratio [OR] 0.86; 95% CI
0.77–0.97) [12]. In this study of apixaban vs
warfarin, we did not observe any significant
interaction between treatment and race for
recurrent VTE, MB, or CRNMB. The treatment
effects of apixaban vs warfarin were consistently
observed between black and white patients.
Similarly, most of the subgroup analyses of the
DOAC pivotal trials in patients with VTE did
not find significant differences in treatment
outcomes by race [6]. More studies are needed
to understand the reasons for the racial dispar-
ity in VTE treatments.
Disparities in VTE treatments also exist
among patients with different SES. A retrospec-
tive analysis of patients with VTE reported that
patients with an income of greater than
US$100,000/year were more likely to receive
Fig. 3 Risk of major bleeding among older patients with VTE stratified by demographic and socioeconomic factors. CI:
confidence interval
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DOAC therapy compared with patients with an
income of less than US$40,000 per year (OR
1.50; 95% CI 1.33–1.69) after controlling for
other factors [12]. To address the treatment
disparity, it is important to understand whether
DOAC treatment effects differ by different SES.
In the current study, we compared apixaban
with warfarin for recurrent VTE, MB, and
CRNMB stratified by SES and by Medicare
Medicaid dual eligibility or LIS which is a group
of vulnerable patients with low income and
complex medical needs. No significant interac-
tion was found between the treatment and SES
or between the treatment and dual eligibility/
LIS for recurrent VTE and MB. The treatment
effects of apixaban vs warfarin on recurrent VTE
and MB were consistently observed regardless of
SES and dual eligibility/LIS. Although a
significant interaction was found between the
treatment and SES on CRNMB, apixaban
patients trended towards a lower risk of CRNMB
across all strata of SES. Additional efforts are
needed to optimize VTE treatments for patients
with low SES.
As with any retrospective claims analysis, the
current study has several limitations. First, the
definitions of recurrent VTE and MB were based
on inpatient claims with primary diagnosis
code for VTE and MB, respectively. While the
use of inpatient primary diagnosis would ensure
that the recurrent VTE and MB events being
captured are indeed major acute events, such
definitions may be too strict to cause underes-
timates of the events. Moreover, the definition
for CRNMB has not been validated in the liter-
ature, although it attempts to align with the
Fig. 4 Risk of clinically relevant non-major bleeding among older patients with VTE stratified by demographic and
socioeconomic factors. CI: confidence interval
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definition suggested by the International Soci-
ety on Thrombosis and Haemostasis [19]. Sec-
ond, the race categories used in the study were
based on what have been defined in the Medi-
care database and a small percentage of patients
in the database had unknown race. It is also
possible that there could be some misclassifica-
tion of race in the database. Third, the SES was
based on zip codes rather than the income of
the patients. However, studies have shown that
zip code level classification of SES is a more
conservative proxy and is often used [30–32].
Fourth, only association rather than causation
could be inferred and hence the results should
be interpreted with caution. Fifth, the baseline
medications included in this study were mostly
limited to those that were likely to increase the
risk of bleeding or clots. This list may not be
comprehensive, and some other important
medications may be missed. Sixth, polyphar-
macy was not adjusted for in the model and
could have an impact on risk of recurrent VTE
and bleeding. Lastly, the results of this study
cannot be generalized to older patients with
other insurances such as Medicare Advantage,
Veterans Affairs, or those who are uninsured.
CONCLUSIONS
In this study of patients with VTE
aged C 65 years, higher incidence rates of
recurrent VTE, MB, and CRNMB were observed
in black vs white patients and patients with
lower vs higher SES. Apixaban had a lower risk
of recurrent VTE, MB, and CRNMB compared to
warfarin. The treatment effects of apixaban vs
warfarin were generally consistent across the
demographic and socioeconomic subgroups.
More studies are needed to identify optimal VTE
management strategies for black patients and
patients with lower SES.
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